MedTrace Logo

Faslodex Advanced Breast Cancer Local Chinese Study

NCT00327769 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2011-01-25

No results posted yet for this study

Summary

This study will evaluate the efficacy and safety of Faslodex as secondary-line treatment compared with Arimidex in oestrogen receptor positive postmenopausal advanced breast cancer.

Conditions

Interventions

DRUG

Fulvestrant

250 mg intramuscular injection

DRUG

Anastrozole

1 mg tablet

Sponsors & Collaborators

Principal Investigators

  • Breast Cancer Established Brands Team Medical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Completion
2007-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00327769 on ClinicalTrials.gov